Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present UCB S.A. (OTC: UCBJY).

Full DD Report for UCBJY

You must become a subscriber to view this report.

Recent News from (OTC: UCBJY)

FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters
BRUSSELS and ATLANTA , Aug. 13, 2018 /PRNewswire/ -- UCB today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for midazolam nasal spray*, an investigational product for the acute treatment of seizures in ...
Source: PR Newswire
Date: August, 13 2018 08:00
Spondyloarthritis Resource Center Provides Information And Tips For Dealing With Chronic Back And Joint Pain
SAN FRANCISCO , Aug. 8, 2018 /PRNewswire/ -- MyHealthTeams and UCB today introduce the Spondyloarthritis Resource Center within MySpondylitisTeam , the social network for people living with spondyloarthritis (SpA). Spondyloarthritis is an inflammatory disease that affects the spine...
Source: PR Newswire
Date: August, 08 2018 10:59
UCB S.A. ADR 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by UCB S.A. ADR in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: July, 26 2018 14:44
Amgen resubmits U.S. marketing application for osteoporosis med Evenity
Amgen (NASDAQ: AMGN ) has refiled its U.S. marketing application seeking approval for EVENITY (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk of fracture. More news on: Amgen Inc., UCB S.A., UCB S.A. ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: July, 13 2018 07:09
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
THOUSAND OAKS, Calif. and BRUSSELS , July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an inves...
Source: PR Newswire
Date: July, 13 2018 01:00
UCB Launches the Autoimmune Motherhood (AIM) Movement(TM) to Empower and Inform Women with Chronic Inflammatory Disease About Family Planning
ATLANTA , July 11, 2018 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the launch of the Autoimmune Motherhood (AIM) Movement to support women living with chronic inflammatory or autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA...
Source: PR Newswire
Date: July, 11 2018 08:00
UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease
BRUSSELS , July 2, 2018 /PRNewswire/ -- NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without levodopa) or in combination with levodopa NEUPRO approval in China reinforces UCB's ongoing...
Source: PR Newswire
Date: July, 02 2018 12:30
New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases
BRUSSELS , June 7, 2018 /PRNewswire/ -- Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) Oral presentation on CIMZIA ® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malform...
Source: PR Newswire
Date: June, 07 2018 01:00
UCB Joins with ILAE and IBE to Encourage World Health Assembly Members to Continue Recognition of Epilepsy as Global Health Priority
BRUSSELS and GENEVA , May 22, 2018 /PRNewswire/ -- Significant gaps in epilepsy management, awareness, and effective treatment access continue around the world Groups are launching a call to action for public and private engagement to join the fight against Epilepsy through a sust...
Source: PR Newswire
Date: May, 22 2018 01:00
CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
BRUSSELS , May 16, 2018 /PRNewswire/ --  Positive top line results from Phase 3 C-AXSPAND study underscore the potential of CIMZIA ® (certolizumab pegol) for non-radiographic axial spondyloarthritis (nr-axSpA), and provide concrete evidence for the high burden of the d...
Source: PR Newswire
Date: May, 16 2018 16:02


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on UCBJY.


Logo for UCB S.A. (OTC: UCBJY)

UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.


Contact Information



Current Management

  • Roch Doliveux / President, CEO
  • Detlef Thielgen / CFO

Current Share Structure

  • Market Cap: $15,200,966,790 - 03/16/2018
  • Issue and Outstanding: 183,365,100 - 12/31/2011


Recent Filings from (OTC: UCBJY)

Post-effective amendment to a previously filed F-6
Filing Type: F-6 POSFiling Source: edgar
Filing Date: September, 29 2017



Daily Technical Chart for (OTC: UCBJY)

Daily Technical Chart for (OTC: UCBJY)

Stay tuned for daily updates and more on (OTC: UCBJY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: UCBJY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in UCBJY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of UCBJY and does not buy, sell, or trade any shares of UCBJY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: